Eaton Vance Management lessened its holdings in Amgen, Inc. (NASDAQ:AMGN) by 3.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,224,287 shares of the medical research company’s stock after selling 37,843 shares during the quarter. Eaton Vance Management owned 0.17% of Amgen worth $212,904,000 as of its most recent SEC filing.
Other hedge funds have also modified their holdings of the company. Baker Ellis Asset Management LLC acquired a new stake in shares of Amgen in the 3rd quarter valued at $108,000. Phocas Financial Corp. acquired a new stake in shares of Amgen in the 2nd quarter valued at $110,000. Barrow Hanley Mewhinney & Strauss LLC boosted its holdings in shares of Amgen by 110.7% in the 4th quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 647 shares of the medical research company’s stock valued at $113,000 after purchasing an additional 340 shares in the last quarter. Taylor Hoffman Wealth Management acquired a new stake in shares of Amgen during the 4th quarter valued at $127,000. Finally, Salem Investment Counselors Inc. boosted its holdings in shares of Amgen by 4.7% during the 2nd quarter. Salem Investment Counselors Inc. now owns 809 shares of the medical research company’s stock valued at $139,000 after acquiring an additional 36 shares in the last quarter. 79.53% of the stock is currently owned by hedge funds and other institutional investors.
In other news, EVP Sean E. Harper sold 1,525 shares of Amgen stock in a transaction dated Wednesday, February 14th. The stock was sold at an average price of $174.18, for a total value of $265,624.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last three months, insiders sold 4,575 shares of company stock valued at $838,064. Corporate insiders own 0.19% of the company’s stock.
Amgen (NASDAQ:AMGN) last announced its earnings results on Thursday, February 1st. The medical research company reported $2.89 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $3.03 by ($0.14). The company had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.84 billion. Amgen had a return on equity of 30.87% and a net margin of 8.66%. The firm’s revenue for the quarter was down 2.7% on a year-over-year basis. During the same period in the prior year, the business earned $2.89 earnings per share. analysts expect that Amgen, Inc. will post 13.25 earnings per share for the current fiscal year.
Amgen declared that its board has authorized a stock buyback program on Thursday, February 1st that allows the company to repurchase $10.00 billion in shares. This repurchase authorization allows the medical research company to purchase shares of its stock through open market purchases. Shares repurchase programs are often an indication that the company’s management believes its stock is undervalued.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 8th. Stockholders of record on Thursday, May 17th will be given a $1.32 dividend. This represents a $5.28 annualized dividend and a dividend yield of 3.14%. The ex-dividend date of this dividend is Wednesday, May 16th. Amgen’s dividend payout ratio (DPR) is presently 41.97%.
AMGN has been the topic of several recent research reports. Vetr downgraded Amgen from a “buy” rating to a “hold” rating and set a $184.25 price objective on the stock. in a report on Wednesday, January 3rd. Royal Bank of Canada reissued a “hold” rating and set a $189.00 price objective on shares of Amgen in a report on Wednesday, January 24th. Barclays cut their price objective on Amgen from $190.00 to $180.00 and set an “equal weight” rating on the stock in a report on Thursday. ValuEngine downgraded Amgen from a “buy” rating to a “hold” rating in a report on Monday, April 2nd. Finally, Piper Jaffray reissued a “buy” rating on shares of Amgen in a report on Tuesday, January 2nd. Two analysts have rated the stock with a sell rating, fourteen have given a hold rating and eleven have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $190.57.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.